Liver cancer is the second most common cancer death cause worldwide, the fourth with the highest incidence, and the third most lethal in Mexico. Due to the bad habits and inadequate nutrition of the Mexican population, it is at a high risk of developing this type of disease. At present, it is difficult to make a practical and safe diagnosis of liver cancer in later stages, and it is even more difficult in early stages. This situation, added to the scarce viability and effectiveness of the treatments, and the lack of reliable national incidence records, anticipate a very low survival rate. That is why it requires a greater attention and understanding of this condition, for the identification of therapeutic targets and new timely treatments. In this article we review the main risk factors for liver cancer, their biological characteristics, current diagnostic methods and new proposals for their detection, allowing us to know the contemporary panorama and contribute to research on this health problem and reduce the high rates of incidence and mortality.
Resúmen
El cáncer hepático es la segunda causa de muerte por cáncer más común a nivel mundial, el cuarto con mayor incidencia y el tercero más letal en México. Debido a los malos hábitos y la inadecuada alimentación de la población mexicana, esta se encuentra en un riesgo elevado de desarrollar este tipo de enfermedad. En la actualidad, es difícil hacer un diagnóstico práctico y seguro del cáncer de hígado en etapas tardías y aún es más difícil en fases tempranas. Esta situación sumada a la escasa viabilidad y efectividad de los tratamientos, y a la carencia de registros fidedignos de incidencia nacional, anticipan una supervivencia muy baja. Es por eso que se requiere de una mayor atención y comprensión de dicho padecimiento, para la identificación de blancos terapéuticos y nuevos tratamientos oportunos. En este artículo revisamos los principales factores de riesgo del cáncer hepático, sus características biológicas, los actuales métodos de diagnóstico y las nuevas propuestas para su detección, permitiendo conocer el panorama contemporáneo y contribuir a investigaciones respecto de este problema de salud y reducir las altas tasas de incidencia y mortalidad.
Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sept | Oct | Nov | Dic |
---|---|---|---|---|---|---|---|---|---|---|---|
- | - | - | - | - | - | - | - | - | 24 | 2 | 7 |
Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sept | Oct | Nov | Dic |
---|---|---|---|---|---|---|---|---|---|---|---|
5 | 22 | 23 | 23 | 12 | 18 | 6 | 17 | 34 | 21 | 10 | 10 |
Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sept | Oct | Nov | Dic |
---|---|---|---|---|---|---|---|---|---|---|---|
9 | 11 | 8 | 6 | 12 | 24 | 4 | 13 | 7 | 9 | 15 | 18 |
Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sept | Oct | Nov | Dic |
---|---|---|---|---|---|---|---|---|---|---|---|
9 | 19 | 13 | 21 | 10 | - | - | - | - | - | - | - |
Alfaro, J. A., Sinha, A., Kislinger, T. y Boutros, P. C. (2014). Onco-proteogenomics: cancer proteomics joins forces with genomics. Nat Methods, 11, 1107e13. https://doi.org/10.1038/nmeth.3138
Assy, N., Nasser, G., Djibre, A., Beniashvili, Z., Elias, S. y Zidan, J. (2009).Características de las lesiones hepáticas sólidas comunes y recomendaciones para el diagnóstico. World J Gastroenterol., 15(26), 3217-3227. https://doi.org/10.3748/wjg.15.3217
Barquera, S., Campos-Nonato, I., Hernández-Barrera, L., Pedroza, A. y Rivera-Dommarco, J. A. (2012). Prevalencia de obesidad en adultos mexicanos. ENSANUT, 55(suppl), S151-S160. https://doi.org/10.21149/spm.v55s2.5111
Chen, Y. Chen, J., Liu, Y., Li, S. y Huang, P. (2015). Plasma miR-15b-5p, miR-338-5p and miR-764 as Biomarkers for Hepatocellular Carcinoma. Med Sci Monit., 21, 1864-1871. https://doi.org/10.12659/MSM.893082
Cornett, P. A. y Dea, T. O. (2015). Diagnóstico clínico y tratamiento. 54 ed. Mcgraw-Hill/Interamericana editores, S.A. de C.V.
Debs, T., Kassir, R., Amor, I. B., Martini, F., Iannelli, A. y Gugenheim, J. (2014). Solitary fibrous tumor of the liver: report of two cases and review of the literature. Nt J Surg, 12(12), 1291-1294. https://doi.org/10.1016/j.ijsu.2014.10.037
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, R. S. y Seeff, L. B. (2000). Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Lin Chem, 46(12), 2027-2049. https://doi.org/10.1093/clinchem/46.12.2027
Flores-Téllez, T. N. J., López, T. V., Vásquez-Garzón, V. R. y Villa-Treviño, S. (2015). Co-Expression of Ezrin-CLIC5-Podocalyxin is associated with migration and invasiveness in hepatocellular carcinoma. PLoS ONE, 10(7), e0131605. https://doi.org/10.1371/journal.pone.0131605
Globocan. (2012). (IARC) Section of Cancer Surveillance.
Gomaa, A. I., Khan, S. A., Toledano, M. B., Waked, I. y Taylor-Robinson, S. D. (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14(27), 4300-4308. https://doi.org/10.3748/wjg.14.4300
Gopal, D. V. y Rosen, H. R. (2000). Abnormal findings on liver function tests. Postgrad Med., 107(2), 100-114. https://doi.org/10.3810/pgm.2000.02.869
Hanahan, D. y Weinberg, R. A. (2000). The hallmarks of cancer. Cell., 100(1), 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
Kitisin, K1, Pishvaian, M. J., Johnson, L. B. y Mishra, L. (2007). Liver stem cells and molecular signaling pathways in hepatocellular carcinoma. Gastrointest Cancer Res., 1(4 Suppl 2), S13-21.
Kumar, V., Abbas, A. y Aster, J. (2016). Patología estructural y funcional. 9 ed. Barcelona: Elsevier.
Li, L. M., Hu, Z. B., Zhou, Z. X., Chen, X., Liu, F. Y., Zhang, J. F., Shen, H. B., Zhang, C. Y. y Zen, K. (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res., 70, 9798-9807. https://doi.org/10.1158/0008-5472.CAN-09-3903
Li, S., Li, J., Fei, B. Y., Shao, D., Pan, Y., Mo, Z. H., Sun, B. Z, Zhang, D., Zheng, X., Zhang M., Zhang, X. W. y Chen, L. (2015). MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ. Chin Med J., 128(7), 941-947. https://doi.org/10.4103/0366-6999.154302
Liu, A. M., Yao, T. J., Wang, W., Wong, K. F., Lee, N. P., Fan, S. T., Poon, R. T., Gao, C. y Luk, J. M. (2012). Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2(2), e000825. https://doi.org/10.1136/bmjopen-2012-000825
Liu, H. (2015). Fruit and vegetable consumption and risk of bladder cancer: an updated meta-analysis of observational studies. Eur J Cancer Prev, 24, 508-516. https://doi.org/10.1097/CEJ.0000000000000119
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., De Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D. y Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med., 359, 378e90. https://doi.org/10.1056/NEJMoa0708857
Maitri, Y., Ferrajoli, A., Sood, A. K., López-Berestein, G. y Calin, G. (2016). MicroRNA Therapeutics in Cancer-an Emerging Concept. EBioMedicine, 12, 34-42. https://doi.org/10.1016/j.ebiom.2016.09.017
Plancarte, R., Guillén, M. R., Guajardo, J. y Mayer, F. (2004). Ascites in cancer patients. Physiopathology and therapeutic options. Rev Soc Esp Dolor, 11, 156-162.
Secretaría de Salud. 2014. Mortalidad. Dirección general de información en salud. México, D.F.
Shyh-Horng, C. y King-Teh, L. (2016). Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach. Elsevier, 32(11), 535-544. https://doi.org/10.1016/j.kjms.2016.09.002
Singal, A., Volk, M. L., Waljee, A., Salgia, R., Higgins, P., Rogers, M. A. y Marrero, J. A. (2009). Meta-analysis: surveillance with ultrasound for earlystage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther., 30, 37-47. https://doi.org/10.1111/j.1365-2036.2009.04014.x
SMeO. (2012). Guía mexicana de tratamiento del hepatocarcinoma avanzado. Gaceta Mexicana de Oncología, 11, Supl. 2.
Song, P. P., Xia, J. F., Inagaki, Y., Hasegawa, K., Sakamoto, Y., Kokudo, N. y Tang, W. (2016). Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol, 22, 262-274. https://doi.org/10.3748/wjg.v22.i1.262
Sun, G., Zhang, C., Feng, M., Liu, W., Xie, H., Qin, Q., Zhao, E. y Wan, L. (2017). Methylation analysis of p16, SLIT2, SCARA5, and Runx3 genes in hepatocellular carcinoma. Medicine, 96(41), e8279. https://doi.org/10.1097/MD.0000000000008279
Sun, H. y Song, T. (2015). Hepatocellular carcinoma: advances in diagnostic imaging. Drug Discov Ther, 9, 310-318. https://doi.org/10.5582/ddt.2015.01058
Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., et al. (2012). Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Journal of Hepatology, 56, 167-175. https://doi.org/10.1016/j.jhep.2011.04.026
Wang, Z., Ding, Q., Li, Y., Liu, Q., Wu, W., Wu, L. y Yu, H. (2016). Reanalysis of microRNA expression profiles identifies novel biomarkers for hepatocellular carcinoma prognosis. Tumour Biol., 37(11), 1-9.
Williams, R. (2014). Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity and viral hepatitis. Lancet, 384(9958), 1953-1997. https://doi.org/10.1016/S0140-6736(14)61838-9
Yao, W. F., Liu, J. W., Sheng, G. L. y Huang, D. S. (2011). Blockade of IGF-IR exerts anticancer effects in hepatocellular carcinoma. Mol Med Rep., 4(4), 719-722.
Yang, Y., Li, M., Chang, S., Wang, L., Song, T., Gao, L., Hu, L., Li, Z., Liu, L., Yao, J. y Huang, C. (2014). MicroRNA-195 acts as a tumor suppressor by directly targeting Wnt3a in HepG2 hepatocellular carcinoma cells. Mol Med Rep., 10(5), 2643-2648. https://doi.org/10.3892/mmr.2014.2526
Yang, Y., Zhao, Z., Hou, N., Li, Y., Wang, X., Wu, F., Sun, R., Han, J., Sun, H., Song, T., Huang, C. y Shao, Y. (2017). MicroRNA 214 targets Wnt3a to suppress liver cáncer cell proliferation. Mol Med Rep., 16(5), 6920-6927. https://doi.org/10.3892/mmr.2017.7483
Zaytseva, Y. Y., Valentino, J. D., Gulhati, P. y Evers, B. M. (2012). MTOR inhibitors in cancer therapy. Cancer Lett, 319, 1-7. https://doi.org/10.1016/j.canlet.2012.01.005